News

NewsAnthony Schwartz2024-09-10T06:24:15-07:00

Abvance Therapeutics Announces $3.9M Program Related Investment from the Helmsley Charitable Trust to Support Development of Its Novel Insulin and Glucagon Combined Formulation

By Steve Daly|September 10th, 2024|Categories: Uncategorized|0 Comments

Abvance Featured in Startup Health

Abvance’s Novel Coformulation of Insulin and Glucagon Could Revolutionize [...]

By Anthony Schwartz|September 28th, 2023|Categories: Uncategorized|0 Comments